LXEO Stock Analysis: Lexeo Therapeutics, Common | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 349m USD | 12M Return: 5.5% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 3.97M
Qual. Beats: 0
Qual. Beats: 0
Warnings
Tailwinds
Seasonality 2.6 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Lexeo Therapeutics is a clinical-stage genetic medicine company headquartered in New York, developing gene therapy candidates for hereditary and acquired diseases with high unmet need, primarily in cardiology and neurology. The company is based in the United States and went public on NASDAQ in November 2023.
Its pipeline includes LX2006 (Friedreich ataxia cardiomyopathy, Phase 1/2), LX2020 (PKP2-associated arrhythmogenic cardiomyopathy, Phase 1/2), LX2021 (preclinical, targeting connexin 43 for inherited cardiac disorders), LX2022 (preclinical, targeting TNNI3 for hypertrophic cardiomyopathy), and LX1001/LX1020/LX1021 (APOE4-associated Alzheimers disease, with LX1001 having completed Phase 1/2). The company was founded in 2017.
Lexeo relies heavily on academic collaborations, most notably a license and research agreement with Cornell University covering the LX1001, LX1004, and FA cardiomyopathy programs. As a clinical-stage biotechnology company, it has no approved products, and its value depends on the progression of its gene therapy pipeline and continued partnership with academic research institutions.
- LX2006 Friedreich ataxia cardiomyopathy phase 1/2 data readout ahead
- FDA breakthrough therapy designation decision for LX2020 PKP2-ACM program
- Cash burn accelerates, secondary equity offering likely needed to extend runway
| Net Income: error (cannot be calculated; needs Net Income TTM and Revenue TTM) |
| FCF/TA: -0.39 > 0.02 and ΔFCF/TA 30.93 > 1.0 |
| NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -0.39 > 3% & CFO -98.0m > Net Income -87.5m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 14.16 > 1.5 & < 3 |
| Outstanding Shares: last quarter (81.2m) vs 12m ago 145.2% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 0.0% > 50% (prev 1.55%; Δ -1.55% > 0%) |
| Interest Coverage Ratio: -477.1 > 6 (EBIT TTM -87.3m / Interest Expense TTM 183k) |
| A: 0.75 (Total Current Assets 200.9m - Total Current Liabilities 14.2m) / Total Assets 250.4m |
| B: -1.60 (Retained Earnings -400.3m / Total Assets 250.4m) |
| C: -0.46 (EBIT TTM -87.3m / Avg Total Assets 188.0m) |
| D: 12.28 (Book Value of Equity 231.5m / Total Liabilities 18.9m) |
| Altman-Z'' = 9.45 = AAA |
As of July 08, 2026, the stock is trading at USD 4.79 with a total of 1,267,757 shares traded. Over the past week, the price has changed by -0.42%, over one month by +13.78%, over three months by -24.09% and over the past year by +5.51%.
Current recommended Stop Loss: 4.30 (which is 10.2% or 1.5 ATR below the current price).
Lexeo Therapeutics, Common has received a consensus analysts rating of 4.57. Therefore, it is recommended to buy LXEO.
- StrongBuy: 4
- Buy: 3
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 20.6 | 330.1% |
P/S = 478.2646
P/B = 1.5094
Revenue TTM = 0.0 USD
EBIT TTM = -87.3m USD
EBITDA TTM = -85.2m USD
Long Term Debt = 4.67m USD (estimated: total debt 7.37m - short term 2.69m)
Short Term Debt = 2.69m USD (from shortTermDebt, last quarter)
Debt = 7.37m USD (from shortLongTermDebtTotal, last quarter) (leases 7.37m already included)
Net Debt = -64.4m USD (calculated: Debt 7.37m - CCE 71.8m)
Enterprise Value = 285.0m USD (349.4m + Debt 7.37m - CCE 71.8m)
Interest Coverage Ratio = -477.1 (Ebit TTM -87.3m / Interest Expense TTM 183k)
EV/FCF = -2.90x (Enterprise Value 285.0m / FCF TTM -98.4m)
FCF Yield = -34.53% (FCF TTM -98.4m / Enterprise Value 285.0m)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 2.12m) / Revenue TTM)
Tobins Q-Ratio = 1.14 (Enterprise Value 285.0m / Total Assets 250.4m)
Interest Expense / Debt = 2.48% (Interest Expense 183k / Debt 7.37m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -69.0m (EBIT -87.3m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 14.16 (Total Current Assets 200.9m / Total Current Liabilities 14.2m)
Debt / Equity = 0.03 (Debt 7.37m / totalStockholderEquity, last quarter 231.5m)
Debt / EBITDA = 0.76 (negative EBITDA) (Net Debt -64.4m / EBITDA -85.2m)
Debt / FCF = 0.65 (negative FCF - burning cash) (Net Debt -64.4m / FCF TTM -98.4m)
Total Stockholder Equity = 184.3m (last 4 quarters mean from totalStockholderEquity)
RoA = -46.54% (Net Income -87.5m / Total Assets 250.4m)
RoE = -47.48% (Net Income TTM -87.5m / Total Stockholder Equity 184.3m)
RoCE = -46.21% (EBIT -87.3m / Capital Employed (Equity 184.3m + L.T.Debt 4.67m))
RoIC = -28.88% (negative operating profit) (NOPAT -69.0m / Invested Capital 238.9m)
WACC = 13.40% (E(349.4m)/V(356.8m) * Re(13.64%) + D(7.37m)/V(356.8m) * Rd(2.48%) * (1-Tc(0.21)))
Discount Rate = 13.64% (= CAPM, Blume Beta Adj.) -> capped to 13.17%
Shares (quarterly) Correlation: 100.00 | Cagr: 62.28%
[DCF] Fair Price = unknown (Cash Flow -98.4m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.19 | # QB: 0
Revenue Correlation: N/A | Revenue CAGR: N/A | SUE: 0.0 | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.28 | Chg30d=-0.69% | Revisions=+50% | Analysts=7
EPS next Quarter (2026-09-30): EPS=-0.31 | Chg30d=+0.61% | Revisions=+70% | Analysts=8
EPS current Year (2026-12-31): EPS=-1.14 | Chg30d=-0.32% | Revisions=+50% | GrowthEPS=+40.9% | GrowthRev=+0.0%
EPS next Year (2027-12-31): EPS=-1.34 | Chg30d=-1.91% | Revisions=+57% | GrowthEPS=-13.8% | GrowthRev=+0.0%
[Analyst] Revisions Ratio: +85% (up=17, down=0)